A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Trial details
- Registry ID
- NCT04880642
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Buloxibutid, Compound 21
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsNCT04880642 | Vicore Pharma AB | Phase 3 | Completed | 2022-04-25Actual |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFNCT04533022 | Vicore Pharma AB | Phase 2 | Completed | 2024-03-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |